Study Group: Physicians who Treat Sepsis (US)
Council Members in this Study Group: 99
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Sabry Ayad
Chairman of Anesthesiology and Critical Care
Westgate Medical Anesthesia Group
Sabry Ayad, MD, is a Member of Westgate Medical Anesthesia Group, a private practice that provides a full range of anesthesia services for local healthcare facilities in Ohio. Through his employment at Westgate Medical Anesthesia Group, he is the Chairman...
Robert ArisAssociate Professor of Medicine
University of North Carolina Chapel Hill - CCRobert Aris, MD, is an Associate Professor of Medicine at the University of North Carolina Chapel Hill. He is the Director of the Pulmonary Hypertension Program, the Lung Transplant Research Program and Inpatient Pulmonary Services. Dr. Aris has expertise...
- Warren Botnick
President
PSS Clinical ResearchWarren Botnick, MD, FCCP, DABSM, is a Partner at Pulmonary and Sleep Specialists in Decatur, Georgia, since March 2003. He is Director of Critical Care Unit and Chief of Medicine at DeKalb Medical Center, Medical Director of Southern Sleep Technologies,...
- George Deitrick
Assistant Professor of Surgery
MOUNT SINAI SCHOOL OF MEDICINE OFGeorge Deitrick, MD, is the Director of Wound Healing Program at the James J. Peters VA Medical Center (Bronx Veterans Medical Research Foundation) in the Bronx, New York. Dr. Deitrick is a General Surgeon and Spinal Cord Injury Physician. He is also...
- Forrest Rubenstein
Cardiac, Thoracic and Vascular Surgeon
Rubenstein Cardiovascular and Thoracic SurgeryForrest Rubenstein, MD, FACS, is a Cardiac, Thoracic and Vascular Surgeon in private practice. Dr. Rubenstein is board certified in General, Cardiovascular and Thoracic Surgery. He has experience in cardiac, thoracic and vascular surgery, aortic surgery,...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
The good news is that these drugs are already approved
October 28, 2009
Triple-combo Drug Shows Promise Against Antiviral Resistant H1N1 | www.medicalnewstoday.com
Adamas has a proprietary mixture of three drugs: amantadine, oseltamivir and ribavirin to treat antiviral resistant strains of novel H1N1 Influenza A.
-
Potential game changer for patients and hospitals regarding C. difficile colitis
July 18, 2009
Rapid DNA Test to Detect Clostridium difficile Infection Approved by FDA Today | www.medscape.com
Clostridium difficile-associated colitis is a disabling, and potentially life-threatening infection. Moreover, hospitals spend great resources in isolating patients with this disease to prevent infection within the hospital. This new technology from Cepheid offers faster, and more accurate diagnosis, leading to potentially quicker treatment for patients, but potentially huge savings for hospitals, that can shorten isolation periods for these patients.
-
18 months too late for this outbreak, but may be the way toward the future.
July 8, 2009
Cadila Pharma-Novavax JV to produce swine flu vaccine | www.business-standard.com
The referenced article states that the joint venture would begin producing swine flu vaccine in two years, possibly based on viral-like particle (VLP) technology. While this is too late to have significant impact in the current pandemic, it points to possible future technologies for vaccine development.
-
April 23, 2009
TB vaccine enters advanced clinical trials at Oxford | timesofindia.indiatimes.com
The decades old BCG vaccine needs to be replaced. It offers at best 50% efficacy, can at times cause severe reaction, and renders subsequent tracking of active TB difficult to impossible. This article describes a trial in South Africa to assess the effectiveness of a new candidate vaccine in infants already immunized with BCG. There is a significant reason why there are so few specifics in the press release.
-
Safety profile similar to placebo! Can't do better than that.
April 6, 2009
Intercell announces European approval of new vaccine, IXIARO®, to prevent Japanese Encephalitis | www.pipelinereview.com
Intercell vaccine is as effective as current JE-VAX, with side-effects similar to placebo. The current JE-VAX is used parsimoniously because of the risk of hypersensitivity reactions. This new vaccine will likely supplant and replace the current vaccine. However, until it has US approval, there may not be recommendations from CDC regarding its use.
Members in this Study Group include these company types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Academic Institution*
- Government/Military Hospital or Clinic
- Other Freestanding Healthcare Facility
Members in this Study Group often have these job titles:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Owner
- Medical Director
- Physician - Department Chair
- Director
Related Study Groups
GLG Live Meetings with this Study Group's Leading Experts (?)
June 14, 2006 | Boston
GLGi: Sleep Disorders: The Global Market for Devices and Pharmacologic TreatmentsJune 14, 2006 | New York
GLGi: Sleep Disorders: The Global Market for Devices and Pharmacologic TreatmentsGLG Webcasts & Teleconferences
Leading Experts in Physicians who Treat Sepsis (US) have not participated in any GLG webcasts.